What is Swoop?
Swoop operates a HIPAA-certified and NAI-accredited system designed to educate patients about disease states and therapeutic interventions. By leveraging artificial intelligence and machine learning, combined with a vast dataset of over 300 million de-identified patient profiles and 65 billion anonymous consumer interactions, Swoop identifies unique patient audiences. This enables precise activation of patient populations and their healthcare ecosystems through cross-channel marketing strategies, ultimately driving optimal conversion and increased prescription lift.
How much funding has Swoop raised?
Swoop has raised a total of $13.4M across 4 funding rounds:
Series A
$4.8M
Other Financing Round
$3M
Series B
$3.5M
Debt
$2.1M
Series A (2011): $4.8M with participation from Valhalla Partners, U.S. Venture Partners, and General Catalyst Partners
Other Financing Round (2012): $3M led by Valhalla Partners and U.S. Venture Partners
Series B (2013): $3.5M supported by U.S. Venture Partners
Debt (2014): $2.1M featuring U.S. Venture Partners
Key Investors in Swoop
Valhalla Partners
Valhalla Partners is a venture capital firm that partners with entrepreneurs to build technology companies, offering advice and best practices based on extensive experience in investing and executive leadership.
U.S. Venture Partners
U.S. Venture Partners (USVP) is a Silicon Valley venture capital firm specializing in early-stage investments across cybersecurity, enterprise software, consumer products, and healthcare, leveraging its network to support company growth.
General Catalyst Partners
General Catalyst is a venture capital firm that invests in transformational business opportunities, supporting entrepreneurs and management teams with capital and operational expertise across technology, healthcare, and financial services.
What's next for Swoop?
With a history of consistent capital infusion, including major enterprise-level funding, Swoop appears to be in a robust scaling phase. The recent strategic investment signals confidence from backers in its innovative approach to patient engagement and data-driven marketing within the pharmaceutical industry. This financial backing is expected to fuel further development of its AI-powered platform, expansion into new markets, and enhancement of its capabilities in leveraging real-world evidence and social determinants of health data to refine its patient segmentation and activation strategies.
See full Swoop company page
